Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone know when it will convert to cash in our trading accounts?
I suspect there might be some law suits filed by some law firms for screwing us at this price. If there is, I will be joining them.
It is definitely trading. on my Etrade market trader it is at $6.85 now and 250,356 shares have traded. It hit a high of 7.04 about 30 minutes ago.
Etrade Market trader shows bid of 6.24 and ask of 6.25 with 7065 shares traded already
I agree, I have owned this stock for several years because of the promising initial study results. I am a physician and the Lancet results and the study results today on the platelets is truly game changing. I know the eye studies will take a couple years unless they got early approval from the FDA for compassionate care treatment. The platelet studies will now need to be tested in humans. The good thing is once these studies start it will not take long to see results. They could easily recruit hundreds to thousands of patients in a controlled study in a very short period of time and they will have initial results within days based on the life of platelets as to whether they are as effective in humans as natural platelets are. I have not sold any of my stock but I am still totally confused as to why there was not a major move up. I understand the dilution but when you talk about a market of multi billions of dollars the dilution is nothing.
You are wrong. I have posted several times in the past when I get it on wednesday whether it is in it. As proof when you read it tomorrow the lead artice is
981 Lessons from a Public Health Emergency- Importation of Wild Poliovirus to Israel.
As I said it is released to the public on thursdays but physicians with a prescription get it on wednesdays.
Physicians get the NEJM on wednesdays and released to the public on thursdays
Juat got this weeks NEJM. No article this week. Hopefully soon. GLTA
ACTC appoints Paul Wotton, Ph.D president and CEO
One of the scientists at ACTC leaked at a conference a couple months ago that there would be preliminary results published in the NEJM in the near future. The company backed away from that at their last conference call but they also did not deny that there might be one.
I thought they announced that they would not release it in the press and only in a peer reviewed journal. They said they would not say whether it would or would not be in a journal article so they left it open as to when it could be.
NEJM just arrived. No article this week.
NEJM just arrived. No article this week. I will be on vacation in Florida next week so won't be able to let you know next week. Hopefully it comes out soon. GLTA
I would hope they would go with a JV and not a buyout when the time comes. When you think of the potential market of $30 billion, if they did a JV and you gave it a forward earnings of even 10, think of what this stock would be worth even with over 3 billion shares. If they got bought out, they would not even come close to that number. All this presumes the science does work which initial signs show it does. They just need to be able to hold on with finances and get through their bad governance until they get enough proof. This also does not include the platelet transfusion potential which would be billions of dollars. I know that is years down the road but would change everything.
NEJM just arrived. No article this week. Hopefully soon. GLTA
well no article in this weeks NEJM. It just came out online. Not sure what caused the move today but hopefully it continues.
The New England Journal of Medicine
HOMEARTICLES & MULTIMEDIAISSUESSPECIALTIES & TOPICSFOR AUTHORSCMEAdvanced
Search
Table of Contents
FIND AN ISSUE
By Volume and Issue
By Date
Current Issue
Recent Issues
February 27, 2014
February 20, 2014
February 13, 2014
Browse all past issues
Prev IssueNext Issue
TABLE OF CONTENTS FOR
Current Issue
March 6, 2014 Vol. 370 No. 10
Audio Summary of this Issue
ListenDownload
PERSPECTIVE
889-891
Death in Pregnancy — An American Tragedy
J.L. Ecker
Free Full TextAudio
891-894
Accepting Brain Death
D.C. Magnus, B.S. Wilfond, and A.L. Caplan
894-896
Beyond Repeal — A Republican Proposal for Health Care Reform
T.S. Jost
Free Full Text
896-899
A Legal Victory for Insurance Exchanges
A.R. Gluck
Free Full Text
ORIGINAL ARTICLES
901-910
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
P. Tebas and Others
Comments
911-920
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
Q. Zhou and Others
921-931
Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy
P. Navon Elkan and Others
932-942
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
A. Bill-Axelson and Others
CME
943-949
Brief Report: Mutant Cohesin in Premature Ovarian Failure
S. Caburet and Others
REVIEW ARTICLE
950-957
Global Health: Global Supply of Health Professionals
N. Crisp and L. Chen
Free Full TextCMEInteractive/MultimediaComments
IMAGES IN CLINICAL MEDICINE
958
Neonatal Lupus
M. Khaleel and M. Puliyel
Free Full Text
e15
Frank's Sign
G. Griffing
Free Full Text
CLINICAL PROBLEM-SOLVING
959-966
Wasting Away
O.-P.R. Hamnvik, C.B. Becker, B.D. Levy, and J. Loscalzo
CMEComments
EDITORIAL
968-969
Engineering Cellular Resistance to HIV
M.A. Kay and B.D. Walker
CLINICAL DECISIONS
e16
Cardiac Screening before Participation in Sports — Polling Results
J.A. Colbert
Free Full Text
In November, we invited you to share your opinions about whether young athletes should be required to undergo cardiac screening before they participate in organized sports and what tests should be included if screening is performed. We now present the polling results.
PDFSave
Has anyone heard what happened with the patient who presented at the conference today? Maybe word has gotten out and that is why the stock is moving.
I suspect if it was in this weeks NEJM we would have seen some huge increase in volume as word will travel very quickly.
unfortunately the NEJM did not arrive in todays mail. This is the second week it didn't come in on wednesday. We will have to wait till tonight to get online and see if there is an article. GLTA
I think you can get online after 5pm tonight to see it. One thing I was thinking about is the researchers are not allowed to say anything concerning their results until it is published. I would think the patients would also be under the same restriction. I know last year some results were leaked but they have been pretty tight lipped about their present complete results. If this patient next week is going to talk about his experience and results, does that mean it might be in next weeks NEJM since that is the same day it comes out?
Just got the mail and the NEJM was not in todays mail. We always get it on wednesday so not sure what happened. I guess we will find out tomorrow when it is released to the public.
The mailman hasn't come yet. They must be running late today. I'll let you know when I get it.
FYI, no article in this weeks NEJM. It just came in.
No article in this weeks NEJM. Just got the mail. Hopefully next week or very soon.
As proof when you see it tomorrow, the lead article under the Perspective headline is " Maryland's All-Payer approach to Delivery-System Reform "
no, it actually comes out on wednesdays. Physicians get it a day earlier then what is released to the public. Trust me, I just got it in the mail today and there was no article.
I agree. I have seen it posted in here that it was going to be in the NEJM but I am not sure if it is really true. Does anyone have good evidence that it is going to be in the NEJM?
No article in this weeks NEJM that just came out today, unfortunately. Hopefully next week or very soon.
There is no article this week in the NEJM. As a physician, we get it a day earlier and I just got my mail. It is not in this weeks journal. Hopefully it will be in the next one because I like everyone else wants to see some results.
I agree that our votes won't matter and it will pass since they control the majority of shares. I'm still voting no to send even a small message of my discontent.
well, unless I hear something positive from GR in the next few days, I am voting no with my 450k shares for the R/S. He said he would only do it from a position of strength and I don't see any position of strength right now. I am frustrated with this company right now. They have done little to give us stockholders confidence lately.
Unfortunately what he said back then is not what he is doing now. I have not seen any new information that says we are now doing a R/S from a position of strength. We are doing it after a massive dilution and after Dr. Lanza sells into strength and GR gets a huge bonus in shares. Only 5 patients have been injected after 9 months. Unless GR releases some new results or a possible J/V in the next few weeks, I'd like to see what his definition of a position of strength is. I think he owes us an explanation of what is the position of strenght we are in.
Anyone hear anything recently about why they are going so slow enrolling patients. It has now been 7 months since the first patient was injected and we have a total now of 4 patients injected. They have added another site in the U.S. but I would have thought they would have picked up the pace enrolling these patients. At the rate they are going, it will take 4 years to enroll the 24 patients. I know they agreed with the FDA to do a rolling enrollment in case there were any issues but it just seems like they need to start injecting more patients. There are millions of patients out there with the disease so it shouldn't be too difficult to find the right patients to inject.
Too bad there wasn't an ETF that just invested in stem cell companies. There are several companies out there now with incredible potentials. It is too difficult to know which ones are going to make it and which ones aren't. Stem cells are going to be the future of medicine but which companies lead is anyone's guess. I would definitely put money into an ETF that just dealt with stem cells.
oh come on. You and everyone else in here knows that the next year will determine the future of this company. If the phase I/II trials continue to show the same favorable results, pharma will be all over them for a JV or buyout. They would not wait for the phase III/IV trials. They have enough cash with the present A/S now to sustain them for about 2 years. I don't believe they will need to do any further dilution. If the next set of patients don't continue to show the same results then they are in trouble. I believe in the science of this and do think it will continue to show favorable results especially when they start treating patients with less severe disease. 2012 is going to be the make or break year for this company and I think it is going to make it and thrive and we will all see significant profits. Only time will tell but this is the year.
Does anyone know for a fact whether all the shares have been released to the bond holders and if not how many have been released so far? It still lists them as having 1.7 billion OS shares.
Be very careful when you see trials like this. These are not FDA approved trials so alot of these are gimmicky clinics that can show whatever results they want since they are not controlled trials. Just like a makeup that is advertising they have stem cells and it gets rid of wrinkles. Unfortunately they can make claims like that and the FDA doesn't go after them. If it is not an FDA approved trial, I would be very leary of any results.
I hope you aren't talking about me. I have said time and again that I believe in this company, stock and the science. That does not mean I can't post concerns about a company or something a leader of the company does. If you only expect to hear positive things then something is wrong. I have been very critical of DDLS and one other on this board since they post the same thing about this stock going to .06 or lower 10 times a day. I don't mind anyone's opinion about this company and saying it might go to .06 but don't need to hear it is going to .06 or the opposite of $100 multiple times a day. I also hate when someone has no stock in this company and continues to make negative comments. This company has great potential but don't accuse someone who has anything negative to say about it is trying to talk this stock down. I started buying this stock 18 months ago and will continue to buy more at times. I wish only the best for this company but that doesn't mean you can't be critical at times. It is nothing that most on this board have at least been concerned about.
Mafiaxx, I agree that I am very disappointed with Lanza selling his shares but I don't believe at all this is a pump and dump company. I have some concerns about the study results as a physician myself but believe the science will work. Ellysee as a serious investor as I know you are based on your posts, you know insider buying and selling is a very important metric on judging a company. If I am not mistaken this company has not had any insider actual buying except for awarding of options. There are 2 faces of this company and that is GR and Lanza. When you see someone selling after a major study release it is very disappointing. Yes he has a right but I am still very disappointed after you had major national news coverage. Like I have said before I now have 450k shares at a cost basis of just over .15. I have no intention of selling but I am disappointed in Lanza as a leader in this company which he is.
You are absolutely right but you at least have to admit you were disappointed when you saw he sold over 7 million shares. That is all we are saying. I am in for the long haul with this company and have not sold any of my shares. That doesn't mean we can't be critical and disappointed when we get news like that.